119 related articles for article (PubMed ID: 35308002)
1. Prognostic importance of molecular-like classification in gastroesophageal junction tumors (Izmir Oncology Group [IZOG] study).
Özdemir Ö; Argon A; Yakan S; Salman T; AlacacIoğlu A
Pol J Pathol; 2021; 72(4):315-323. PubMed ID: 35308002
[TBL] [Abstract][Full Text] [Related]
2. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist.
Tsuruta S; Ohishi Y; Fujiwara M; Ihara E; Ogawa Y; Oki E; Nakamura M; Oda Y
Hum Pathol; 2019 Jun; 88():27-38. PubMed ID: 30946937
[TBL] [Abstract][Full Text] [Related]
3. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery.
Ramos MFKP; Pereira MA; de Mello ES; Cirqueira CDS; Zilberstein B; Alves VAF; Ribeiro-Junior U; Cecconello I
World J Clin Oncol; 2021 Aug; 12(8):688-701. PubMed ID: 34513602
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
[TBL] [Abstract][Full Text] [Related]
5. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes.
Angerilli V; Pennelli G; Galuppini F; Realdon S; Fantin A; Savarino E; Farinati F; Mastracci L; Luchini C; Fassan M
Virchows Arch; 2022 Oct; 481(4):545-552. PubMed ID: 35925389
[TBL] [Abstract][Full Text] [Related]
7. Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.
Yoon JY; Brezden-Masley C; Streutker CJ
BMC Cancer; 2020 Sep; 20(1):860. PubMed ID: 32894084
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications.
Koh J; Lee KW; Nam SK; Seo AN; Kim JW; Kim JW; Park DJ; Kim HH; Kim WH; Lee HS
Oncologist; 2019 Dec; 24(12):e1321-e1330. PubMed ID: 31371521
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastroesophageal cancer in a large Belgian cohort.
De Meulder S; Sagaert X; Brems H; Brekelmans C; Nafteux P; Topal B; Verslype C; Tejpar S; Van Cutsem E; Dekervel J
Acta Gastroenterol Belg; 2022; 85(1):1-5. PubMed ID: 35304987
[TBL] [Abstract][Full Text] [Related]
11. Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma.
Dong H; Xie L; Tang C; Chen S; Liu Q; Zhang Q; Zheng W; Zheng Z; Zhang H
Clin Transl Oncol; 2014 Sep; 16(9):783-91. PubMed ID: 24356933
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
13. Are Immunohistochemical Markers Useful in Phenotypic Gastric Cancer Classification?
Di Pinto F; Armentano R; Arborea G; Schena N; Donghia R; Valentini AM
Oncology; 2020; 98(8):566-574. PubMed ID: 32316005
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan.
Koriyama C; Akiba S; Itoh T; Kijima Y; Sueyoshi K; Corvalan A; Herrera-Goepfer R; Eizuru Y
Int J Mol Med; 2002 Nov; 10(5):635-9. PubMed ID: 12373307
[TBL] [Abstract][Full Text] [Related]
19. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
20. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
